Wolfgang Miesbach: Adenoassociated Virus-Based Gene Therapy for Haemophilia
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn about a recent article he and his colleagues co-authored, adding:
“Gene Therapy for Haemophilia: From Experimental Concept to Clinical Reality. Written by young investigators (haematologists and hepatologists), for young investigators. Delighted to share the new educational review published in the Journal of Thrombosis and Haemostasis (JTH), providing a comprehensive overview of adenoassociated virus (AAV)-based gene therapy for haemophilia:
- Clinical Efficacy Demonstrated:
Phase III trials of valoctocogene roxaparvovec (haemophilia A) and etranacogene dezaparvovec (haemophilia B) have shown durable factor expression for up to 5 years, with persons with haemophilia achieving factor levels in the normal or mild haemophilia range and significant reductions in bleeding rates. The FIX-Padua variant has proven particularly transformative, enhancing treatment efficacy 5- to 8-fold.
- Hepatological Considerations:
Approximately 20% to 90% of persons with haemophilia experience transaminase elevation postinfusion, requiring immunosuppressive management and close hepatologic monitoring. This underscores the essential role of hepatologists within the multidisciplinary care team and the importance of comprehensive liver health assessment prior to treatment.
- Future Directions:
Whilst AAV-based therapies represent a remarkable advance, several developments promise to further enhance outcomes: alternative vectors to address neutralising antibody limitations (expanding access for seropositive patients), enhanced factor variants for improved efficacy, and gene editing technologies including CRISPR-Cas9 for precise genetic correction.
- Critical Challenges Remain:
Long-term durability beyond 5 years, immune response management, standardised care pathways, and equitable global access require continued attention and collaborative research efforts.
Congratulations to Pascal Hoffmann, Niccolò Bitto, and Vincenzo La Mura.”
Title: Overview of gene therapy for hemophilia: questions and answers to navigate the innovation
Authors: Pascal Hoffmann, Niccolò Bitto, Vincenzo La Mura, Wolfgang Miesbach
Read the Full Article on Journal of Thrombosis and Haemostasis.
Find more posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Feb 4, 2026, 08:45Robert Sidonio: No Accumulation of FVIII or VWF and No Thrombotic Events in Severe VWD
-
Feb 4, 2026, 08:35Allen Seylani: Impact of a Treat-to-Target Urate-Lowering Strategy on Cardiovascular Events
-
Feb 4, 2026, 08:33Jan Sloves: Integrating Structure, Mechanics, Hemodynamics, and Microvascular Perfusion in Vascular Ultrasound
-
Feb 4, 2026, 08:16Bartosz Hudzik: Extended Anticoagulation in Cancer-Associated VTE – Who Is at Higher Bleeding Risk?
-
Feb 4, 2026, 08:07Fayad Al-Haimus: Is Giving TXA Within ‘3 Hours’ Really Enough in Major Trauma?
-
Feb 4, 2026, 08:05Stephen Cornelissen Honors the Life-Saving Impact of Blood Donation on World Cancer Day
-
Feb 4, 2026, 07:55Louise St Germain Bannon: Proud to Share This Important Constituency Statement Delivered at EB158
-
Feb 4, 2026, 07:45Laure Morimont and Colleagues on Early Prediction of VTE Risk with COCs
-
Feb 4, 2026, 07:29Heghine Khachatryan: Behind These Photos Are Not Just Official Meetings…